Biotechnology

RMTG's ISSCA Division to Host ISSCA 125 Global Summit in Cancún, Mexico

September 21, 2026 7:01 AM

Regenerative Medical Technology Group Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the 2026 ISSCA Global Summit, ISSCA 125, taking place September 25-27 at the JW Marriott Cancún Resort & Spa. ISSCA is the International Society for Stem Cell Application, the physician-education platform operated within Global Stem Cells Group....

Read more

Alligator Bioscience Announces Preliminary Outcome in Rights Issue

September 21, 2026 6:00 AM

Alligator Bioscience (STO:ATORX) - The Board of Directors of Alligator Bioscience AB ("Alligator Bioscience" or the "Company"), today announces the preliminary outcome of the rights issue of units that was announced on 23 July 2026 (the "Rights Issue"). The preliminary outcome indicates that the Rights Issue has been subscribed to approximately 17.1 percent with and without exercise of unit rights, of which approximately 16.7 percent were...

Read more

RMTG's ISSCA Division Launches Integrative Fellowship in Point-of-Care Regenerative Medicine through ISSCA AI(TM) Strategy

September 17, 2026 7:02 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the launch, through its ISSCA division, of a new Integrative Fellowship in Point-of-Care Regenerative Medicine. The fellowship is designed as ISSCA's most comprehensive credential and as a longer-duration educational offering within ISSCA's...

Read more

New Meta-Analysis Strengthens Clinical Evidence for DiviTum TKa in Metastatic Breast Cancer

September 17, 2026 3:15 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announced the publication of a new systematic review and meta-analysis in the peer-reviewed journal The Breast. The study brings together the available clinical evidence for circulating thymidine kinase activity (TKa) in hormone receptor-positive metastatic breast cancer and provides the strongest evidence to date...

Read more

Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum

September 17, 2026 2:20 AM

Vicore Pharma Holding AB (publ) (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists, today announced that the company will participate in the Stifel 2026 Virtual Immunology and Inflammation Forum. Location: Virtual Format: Presentation and 1×1 meetings Presentation Date and Time: Thursday, September 24, 2026, 8:30-8:55 AM ET Participants:...

Read more

Faron Pharmaceuticals LTD: Holding(S) In Company

September 17, 2026 2:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)...

Read more

Rarity Bioscience Launches Ultra-Sensitive KIT D816V Assay, a New Benchmark for Molecular Testing in Systemic Mastocytosis

September 17, 2026 1:00 AM

Rarity Bioscience today announced the launch of the breakthrough superRCA Ultra-Sensitive KIT D816V Kit RUO, an ultra-sensitive assay for quantitative detection of the KIT D816V mutation. Developed in close collaboration with leading experts from Blueprint Medicines, a Sanofi company, and internationally recognized specialists in systemic mastocytosis (SM), the assay enables accurate and quantitative detection of KIT D816V at variant allele...

Read more

Announcement from the Annual General Meeting in Biovica International AB

September 16, 2026 12:20 PM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The annual general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 16 September 2026 and the following resolutions were passed by the meeting. Adoption of the income statement and balance sheet The annual general meeting resolved to adopt Biovica's income statement and balance sheet as well as the consolidated income statement and consolidated...

Read more

enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series

September 16, 2026 8:50 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced the launch of "WTF Rob Berman" a new video series that provides the information that investors need to know, in straight talk, with no corporate spin. Hosted by enVVeno Medical CEO Rob Berman, the WTF series is designed to go beyond the usual scripted corporate answers used by public company CEOs. Instead, investors will get a candid, accessible and...

Read more

Revalia Bio Taps Former Lilly and Verily Exec to Lead Next Growth Phase

September 16, 2026 8:00 AM

Revalia Bio (Revalia), which generates novel drug development data using functioning donated human organs, today announced the appointment of Casimir Starsiak III (Caz) as President and Chief Executive Officer, with co-founder Greg Tietjen, Ph.D., stepping into the role of Chief Innovation Officer. Starsiak will lead commercial expansion efforts, pharmaceutical partnerships, and operational scale up as the company builds on initial platform...

Read more

Tempo Therapeutics Closes Oversubscribed $14.5 Million Financing to Advance MAP(TM) Regenerative Technology

September 16, 2026 7:02 AM

Tempo Therapeutics, Inc. ("Tempo"), a clinical-stage regenerative medicine company pioneering synthetic biomaterials designed to promote the formation of healthy, functional tissue, today announced the closing of an oversubscribed $14.5 million financing round led by Galaxy Sirius Partners, with participation from Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation - JJDC, Inc., Gideon Strategic...

Read more

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

September 16, 2026 7:00 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company advancing its Deoxyribonuclease ("DNase") technology, and Santersus AG ("Santersus"), a privately held therapeutic medical device company advancing its NucleoCapture® selective blood purification platform, today announced that they have entered into a definitive share exchange agreement pursuant to which Xenetic will, subject to stockholder approval, acquire all of...

Read more

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit

September 14, 2026 11:00 PM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company developing drug candidates for diseases with limited treatment options, today announced that Dr. Frederick D. Sancilio, Chairman and Chief Executive Officer, will present clinical and preclinical data for Conjugated Psilocin™ (L-130) at the 9th Neuropsychiatric Drug Development Summit, held September 15-17, 2026 in Boston,...

Read more

Bora Biologics Selected to Develop, Scale Up, and Supply RAPClot(TM) Protein Supporting Terumo's Japan Launch of RAPClot Blood Collection Tubes

September 14, 2026 7:45 AM

Bora Biologics, a U.S.-anchored biologics contract development and manufacturing organization (CDMO) built for licensed supply, today announced that it has entered into a long-term supply agreement to provide recombinant RAPClot™ protein for Q Sera Pty Ltd. The agreement supports Q Sera's commercialization pathway with Terumo Corporation for the Japan launch of VenoJect® II RAPClot blood collection tubes, marking the first commercial...

Read more

Regenerative Medical Technology Group, Inc. Details Expanded ISSCA AI(TM) Clinical Intelligence Platform, Including Protocol-Native Engine, Structured Data Assets, and Multi-Line Commercial Model

September 14, 2026 7:01 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), operating through its wholly owned subsidiary Global Stem Cells Group, today issued an expanded technology, data, and commercial overview of the ISSCA AI™ Clinical Intelligence Platform. The update describes a more fully specified, physician-facing system for regenerative and longevity medicine: clinics can upload laboratory PDFs, and the platform is designed to...

Read more

PulpFixin(R) Launches Investment Offering on StartEngine, Inviting Investors to Help Build the Next Generation of Sustainable Lab Materials

September 11, 2026 11:20 AM

PulpFixin®, an innovator in sustainable laboratory products, announces the official launch of its investment offering on StartEngine, marking an important milestone in the company's growth and its mission to bring more sustainable materials to modern science. Founded in 2024 by industry veterans from the biotech and pharmaceutical supplies industry, PulpFixin is developing a growing portfolio of high-performance, pulp-based products designed to...

Read more

Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update

September 11, 2026 9:00 AM

Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today reported financial results for the six months ended June 30, 2026 and provided a corporate and clinical update. "During the first half of 2026, we continued to advance GelrinC® on multiple fronts as we build toward important clinical and commercial milestones in the U.S. and Europe,"...

Read more

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

September 11, 2026 7:00 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here. The presentation, featuring Robert Berman, Chief Executive Officer of enVVeno Medical, provides an overview of the Company and its innovative enVVe® System, as well as recent corporate and clinical...

Read more

Therabene Appoints Oscar L. Kashala, M.D., Ph.D., D.Sc., as President and to Board of Directors

September 10, 2026 5:40 PM

Therabene, Inc., a biotechnology company developing next-generation inhibitors and targeted protein degraders for difficult-to-treat cancers, today announced the appointment of Oscar L. Kashala, M.D., Ph.D., D.Sc., as President of Therabene and a member of its Board of Directors, effective September 4, 2026. Dr. Kashala will continue to serve as the Company's Chief Medical Officer. Dr. Kashala joined Therabene in August 2025 and has played a...

Read more

Faron Announces R&D Day

September 10, 2026 2:15 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system, today announces that it will host an R&D Day for investors, analysts and media on 8 October 2026 at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST). The event will provide an opportunity for Faron's senior management team, together with leading...

Read more